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Background  
Replication-deficient adenovirus vectors containing a pathogen-specific transgene have been used as 
novel vaccines because of their ability to induce strong humoral and cellular responses. However, pre-
existing immunity might reduce the immunogenicity of vectors derived from human viruses, hence, 
use of simian adenoviruses might be preferable. COVID-19 Vaccine AstraZeneca, also known as 
AZD1222 or ChAdOx1-S (recombinant), was developed by the Oxford University, United Kingdom, and 
Astra Zeneca, and is a replication-deficient chimpanzee adenovirus-vectored vaccine expressing the 
full-length SARS CoV-2 spike glycoprotein gene. 
Characteristics of AZD1222 vaccine against COVID-19  
AZD1222 vaccine is a monovalent vaccine composed of a single recombinant, replication-deficient 
chimpanzee adenovirus (ChAdOx1-S (recombinant) ) vector encoding the S glycoprotein of SARS-CoV-
2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; 
the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-
fusion conformation. Adenoviruses are non-encapsulated, icosahedral particles (virions), and contain 
a single copy of the double-stranded DNA genome. The expression cassette for the SARS-CoV-2 spike 
protein fused to the tissue plasminogen activator (tPA) leader sequence uses a modified human 
cytomegalovirus (CMV) promoter and a bovine growth hormone polyadenylation sequence. 
 
The following information is derived from the Product Information by the European Medicine Agency`s 
Committee for Medicinal Products for Human Use (CHMP)[1]:  
Composition 
One dose (0.5mL) contains ChAdOx1-S (recombinant) 5 x 1010 viral particles. 
The vaccine is produced in genetically modified human embryonic kidney (HEK) 293 cells.  
In addition to ChAdOx1-S (recombinant), this product also contains the excipients L-histidine, L-
histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80, ethanol, 
sucrose, sodium chloride, disodium edetate dihydrate and water for injections.  
None of the excipients are of animal or human origin. The excipients are well established for 
pharmaceutical products.  
 
Stability 
Proposed shelf-life of 6 months for the drug substance.  
Shelf-life 
Chemical and physical in-use stability have been demonstrated from the time of vial opening (first 
needle puncture) to administration for no more than 48 hours in a refrigerator (2-8Degrees Celsius). 
Within this time period the product may be kept and used at temperatures up to 30 Degrees Celsius 
for a single period of up to 6 hours. After this time period, the product must be discarded. Do not 
return it to the refrigerator.  
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Drug product description 
The product is a colourless to slightly opalescent solution provided in a multidose vial. There will be 
different presentations available in different regions. The drug product is multidose vial with stoper 
(elastomeric with aluminum overseal).  
Container 
The drug product vials are packaged as 10 vials in a carton. There will be different presentations 
available in different regions. For example: 
Presentations in EU:  
- 4 ml (8-dose) vials  
- 5 ml (10-dose) vials 
 
Presentations via COVAX: 
- 5 ml (10-dose) vials 
 
Serum Institute India (SII)’s Covishield is expected to be available in a number of presentations: 
- 1 dose – 0.5 mL per vial 
- 2 dose – 1.0 mL per vial 
- 5 dose – 2.5 mL per vial 
- 10 dose – 5.0 mL per vial 
- 20 dose – 10 mL per vial 
 
Pharmacokinetics 
Two biodistribution studies were performed which suggest that, after injection, the virus does not 
replicate, or persist, and does not biodistribute beyond the injection site in a way that would be 
clinically significant. 
Reproductive and developmental toxicity 
Both a dose-range study (study 490838) and the main GLP embryo-foetal development study (study 
490843) were completed. In top-line results from main study (Study 490843), there were no test item-
related effects seen for dams in-life including at the injection site, for female reproduction, fetal or 
pup survival, pup physical development and no abnormal gross pathology findings in pups prior to or 
post weaning or in dams in either phase. There were no test item-related foetal external, visceral or 
skeletal findings. The audited report is due in mid-February 2021. 
Lactation 
Considering potential use of this vaccine in women who are breastfeeding, there are no studies at this 
time to document safety. Studies are being planned to address these questions.  
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Pre-clinical studies 
Note: The following information is derived from scientific publications. Those publications used the 
term “ChAdOx1-S (recombinant)” which is equivalent to AZD1222. 
 
The efficacy of ChAdOx1-S (recombinant) was assessed in rhesus macaques. Six animals per group 
were vaccinated using a prime-only regimen (28 days before challenge) or a prime–boost regimen (56 
and 28 days before challenge) intramuscularly with 2.5 × 1010 ChAdOx1-S (recombinant) virus particles 
each. As a control, six animals were vaccinated via the same route with the same dose of ChAdOx1-S 
(recombinant) green fluorescent protein (GFP) (one animal was vaccinated 56 and 28 days before 
challenge and five animals were vaccinated 28 days before challenge). No adverse events were 
observed after vaccination. Spike-specific antibodies were present as early as 14 days after 
vaccination and were significantly increased after the second immunization (two-tailed signed-rank 
Wilcoxon test). Endpoint IgG titres of 400–6,400 (prime) and 400–19,200 (prime–boost) were 
measured on the day of challenge. Virus-specific neutralizing antibodies were also significantly 
increased after secondary immunization (two-tailed signed-rank Wilcoxon test) and detectable in all 
vaccinated animals before challenge (5–40 (prime) and 10–160 (prime–boost)), whereas no virus-
specific neutralizing antibodies were detected in control animals. IgM antibodies were present in the 
serum after vaccination on the day of the challenge in six out of six prime–boost and two out of six 
prime-only animals SARS-CoV-2 spike-specific T cell responses were detected on the day of challenge 
by IFNγ ELISpot assay after the stimulation of peripheral blood mononuclear cells with a peptide 
library that spanned the full length of the spike protein. No statistically significant difference in the 
magnitude of the response was found between the prime–boost and prime-only group (Mann–
Whitney U-test, P = 0.3723). As previously reported6, vaccination with ChAdOx1-S (recombinant) 
resulted in the induction of neutralizing antibodies against the vaccine vector itself within 28 days of 
vaccination. Nonetheless, a boost vaccination with ChAdOx1-S (recombinant) resulted in a significant 
increase in binding and neutralizing antibodies in NHPs and an increase in the SARS-CoV-2 virus-
neutralizing titre was not significantly correlated with the ChAdOx1-S (recombinant) virus-neutralizing 
titre (two-tailed Pearson correlation, r2 = 0.6493 P = 0.0529). 
 
A post-vaccination SARS-CoV-2 challenge in rhesus macaques was conducted to evaluate protection 
and the potential for vaccine-associated enhanced respiratory disease (VAERD)[2]. Clinical disease 
score in monkeys was reduced, and the vaccine prevented damage to the lungs. A prime-boost 
regimen induced humoral immune responses. Viral loads were reduced in the lungs, but there was no 
reduction in viral shedding from the nose with either prime-only or prime-boost regimens. These 
suggest that ChAdOx1-S (recombinant) may not prevent infection nor transmission of SARS-CoV-2, but 
it may reduce illness. The immune responses were not skewed towards a Th2-type and there was no 
suggestion of enhanced disease following vaccination. Whilst a single dose induced antigen-specific 
antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in 
pigs, with a significant increase in SARS-CoV-2 neutralising titres[3]. 
Clinical studies 
The pivotal safety, efficacy and immunogenicity data informing registration of the vaccine is derived 
from four ongoing studies: 
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• COV001, a Phase 1/2 trial conducted in the UK 
• COV002, a Phase 2/3 trial conducted in the UK 
• COV003, a Phase 3 trial conducted in Brazil, and  
• COV005, a Phase 1/2 trial conducted in South Africa.  
 
Smaller trials using the vaccine are planned or ongoing in other countries, including South Africa, 
Kenya, Russia, Japan and India. In addition, a large phase 3 trial involving about 30,000 participants is 
ongoing in the US, Peru, Chile, Columbia and Argentina, and interim results from this trial are expected 
shortly. 
The primary analysis of vaccine efficacy of COVID-19 Vaccine AstraZeneca (AZD1222) against first 
SARS-CoV-2 virologically-confirmed COVID-19 in the standard dose (SD) SDSD Seronegative for 
Efficacy Analysis Set (any dosing interval) is included as the primary source of data for efficacy reported 
in this background document. Results were generated using the primary efficacy analysis data cut-off 
#2(DCO2) on 07 December 2020.’ These data were made available to SAGE to review. Astra Zeneca 
has given permission for these data to be made public in this background paper.  
Immunogenicity studies in humans 
Study COV001[4-6]  
1077 participants were enrolled of whom 543 were randomised to receive ChAdOx1-S (recombinant) 
and the rest received meningococcal group A,C,W and Y conjugate vaccine (MenACYW) as the control). 
Subsequently some ChAdOx1-S (recombinant) recipients received boosters at different doses and 
dose intervals. Binding antibody (ELISA) responses were consistently detected after one dose and 
substantially boosted following a second dose, correlating with neutralising antibody titres. The latter 
were measured using several methods and were detectable in 32/35 subjects after one dose and all 
after two, reaching titres similar to those in convalescent sera. Both CD4+ and CD8+ T cell responses 
were detected by ELISpot.  
 
Antibody responses were predominantly of IgG1 and IgG3 subclasses, with low levels of IgG2 and little 
detectable IgG4, consistent with a Th1-biased response. Likewise, cytokine secretion from antigen-
specific CD4+ T-cells showed a Th1-bias with increased IFN-gamma and TNF-alpha generation at day 
7 and 14 rather than a Th2-bias (IL-4 and IL-13).  
 
A standard dose (SD; 5 × 1010 viral particles (vp)) booster administered 56 days after the priming dose 
induced a rise in polyfunctional antibody concentrations[7]. These were higher than following low 
dose (LD; 2.2 × 1010 vp or 2.5 × 1010 vp) boosters but not significantly higher than following booster 
doses given at 28 days. These boosters did not measurably increase the magnitude of the T cell 
responses. While anti-adenoviral vector neutralising antibody responses were detectable, their 
presence was not associated with reduced antibody or T cell anti-SARS CoV2 responses to booster 
vaccine doses. 
 
Booster doses[6]: Using a systems serology approach we also demonstrate that anti-spike neutralizing 
antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent 
neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, were 
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substantially enhanced by a booster dose of vaccine. A full booster dose (SD) of vaccine induced 
stronger antibody responses than a dose-sparing half-dose (LD) boost, although the magnitude of T 
cell responses did not increase with either boost dose. A booster dose of ChAdOx1-S (recombinant)is 
safe and better tolerated than priming doses.  
 
StudyCOV002[7]:  
In the first part of this phase 2/3 trial, 560 subjects, in three different age groups(18-55, 55-69 and >70 
years) were enrolled and received either one (older two groups only) or two doses of ChAdOx1-
S (recombinant) or MenACWY (control) vaccine, 28 days apart. Two dose regimens were used, one 
with a low dose (LD) and the other with a standard dose (SD).  
The median anti-spike SARS CoV-2 IgG responses 28 days after the boost dose were similar across the 
three age cohorts, and likewise, the neutralising antibody titres. T-cell responses peaked at day 14 
after a single SD and did not increase significantly after the boost vaccination.  
The antibody response tended to be slightly lower with the LD regimen compared to the SD regimen 
at day 56.  
The rate of seroconversion (> 4-fold increase from baseline) to S-binding antibodies was > 98% at 28 
days after the first dose and >99% at 28 days after the second dose for participants seronegative at 
baseline. The rate of seroconversion with a live neutralisation assay was high (>80%) at 28 days after 
the first dose and >99% at 28 days after the second dose for participants seronegative at baseline.  
ChAdOx1-S (recombinant) appears to be better tolerated in older adults than in younger adults and 
has similar immunogenicity across all age groups after a booster dose[7].  
 
In the COV002 study, some participants assigned to receive SD priming and booster doses in fact 
received a lower than intended priming dose (roughly equivalent to the LD given during the phase 2 
part of the study). The interval between priming and booster doses for all these LDSD subjects was 
also longer than initially foreseen; about 12 weeks. Among subjects who received SD priming and 
booster doses (“SDSD”), there was a range of dose intervals, mostly ranging between 4 and 12 weeks. 
In this group, observed immunogenicity (by immunoassay)[8] following the booster dose increased 
with longer dose interval. Immunogenicity was similar among those given the lower priming dose with 
a longer dose interval and among those given the standard priming dose with a longer dose interval. 
 
Efficacy  
Note: The efficacy analysis reported in this document reflects data from DCO2 (7 December 2020) from 
all four studies, including patients that received two standard doses (SDSD) with any interval between 
doses (ranging from 3 to 23 weeks (21 to 159 days)) 
 
The primary analysis of vaccine efficacy of COVID-19 Vaccine AstraZeneca includes data from all four 
studies: COV001, COV002, COV003, and COV005: 
 
COV001 (UK; Phase I/II): This is an first in human study in adults 18-55 years of age, designed to 
evaluate various dosing regimens, involving single dose or a 2-dose regimen of AZD1222 or MenACWY. 
different dose levels (SD and LD), and various dosing schedules.  
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COV002 (UK; Phase II/III): This study enrolled participants from 19 study sites and targeted individuals 
working in professions with high possible exposure to SARS-CoV-2, such as health and social care 
settings. This study began by enrolling participants aged 18 to 55 years. Only one vaccine dose was 
planned initially but this was increased to two on the basis of immunogenicity findings in Phase 1/2 
studies (COV001). Participants over 55 years of age were also enrolled subsequently and had a shorter 
interval between their first and second doses. Participants received a single dose or a 2-dose regimen 
of AZD1222 vaccine or MenACWY. Most participants had an interval between doses of 4 to 12 weeks 
and about 20% had an interval in excess of this. 
 
COV003 (Brazil; Phase III): This study enrolled participants at high risk of exposure to the virus, 
including healthcare workers, in 6 sites across the country. Recruitment of participants in Brazil began 
a little later than the COV002 (UK) study and they were offered two doses of the vaccine up to 12 
weeks apart (target 4 weeks). Participants receive 2 doses of AZD1222 or MenACWY (first dose)/saline 
placebo (second dose). For less than 2% of participants, the interval between doses was more than 12 
weeks. 
 
COV005 (South Africa; Phase I/II): This study enrolled adults living with and without HIV at 7 sites in 
the country. The study in South Africa started at approximately the same time as the study in Brazil; 
participants received 2 doses of AZD1222 vaccine or saline placebo at a dose interval between less 
than 4 weeks to 12 weeks. There were no doses administered more than 12 weeks apart in the study 
in South Africa. 
 
Women who were pregnant or breast-feeding were excluded from all studies. 
 
Baseline demographics were well balanced across the vaccine and control treatment groups. In the 
pooled analysis, among the participants who received the vaccine DCO2 (7 December 2020) from all 
four studies, including patients that received two standard doses (SDSD) with any interval between 
doses, 90.2% of participants were 18 to 64 years old (with 9.8% aged 65 or older); 54.4% of subjects 
were female; 71.8% were White, 11.8% were Black and 3.4% were Asian. 2,592 (36.0%) participants 
had at least one pre-existing comorbidity (defined as a BMI ≥30 kg/m2, cardiovascular disorder, 
respiratory disease or diabetes).  
 
The primary analysis of the trial results was conducted when participants had been followed for a 
median of 133 days after the first dose and 80 days after the second vaccine dose. 
 
Efficacy against Covid-19 
The primary endpoint was specified as efficacy against symptomatic Covid-19 at greater than or equal 
to 15 days after the second dose among participants who were seronegative at trial entry. 14,380 
participants were eligible for inclusion in the efficacy analysis (43% UK, 47% Brazil, 10% South Africa) 
among whom there were 271 Covid-19 cases with onset ≥ 15 days post dose 2, with 74 cases in the 
vaccinated group and 197 in the control group with the estimate of vaccine efficacy (VE) being 63.09% 
(95% confidence interval (CI) 51.81 to 71.73).  
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Only about 9.8% of participants were aged 65 years or older and among these there were only 12 
cases of Covid-19, 4 in the vaccine groups and 8 in the control group (VE = 51.91%; 95% CI -59.98% to 
85.54%), based on >= 15 days after the second dose of vaccine (7 December 2020 data cut). 
 
Exploratory analyses were conducted of vaccine efficacy >= 15 days after the second dose according 
to the interval between the first and second doses. For about 59% of participants the interval was 4-
8 weeks, 22% 9-12 weeks and 16% more than 12 weeks. The estimates of VE increased significantly in 
these 3 groups, being 56%, 70% and 78% respectively. 
 
In the first 21 days after the first dose there was no difference in Covid-19 incidence between vaccine 
and control groups. From 22 days after the first dose up to the time of the second dose or up to 12 
weeks after the second dose there were 18 cases of Covid-19 in the vaccine group and 63 cases in the 
control group (VE=71.42% 95% ; CI (51.11, 84.08)). The interval between first and second doses varied 
but up to 12 weeks there was no evidence of a decline in efficacy.  
 
Efficacy against Covid-19 hospitalisation (WHO clinical progression scale ≥4) 
In the total trial population, there were 24 cases of hospitalised Covid-19, 2 in the vaccine group and 
22 in the control group. The corresponding numbers in the periods at any time from ≥22 days after 
the first dose were 0 in the vaccinated group and 14 in the control group. For the period from 15 or 
more days after dose 2 were, respectively, 0 and 8 hospitalized cases.  
 
Efficacy against severe Covid-19 (WHO clinical progression scale ≥ 6) 
In the total population, there were only 3 cases of severe COVID-19, all in the control group.  
 
Summary 
Evidence of efficacy emerged from about 22 days after the first vaccine dose. The vaccine was 
efficacious against laboratory-confirmed Covid-19 from 22 days after the first dose and persisted until 
at least 12 weeks until a second dose was given (VE=71.42%). The primary trial endpoint was efficacy 
measured more than ≥15 days after the second vaccine dose until the end of the data date cutoff, 
which was, on average, about 2 months (mean 58 days; median 66 days) after the second dose and 
during this period the vaccine continued to be efficacious (VE=63.09%). Exploratory analyses indicated 
that efficacy following the second doses increased with increasing intervals between the first and 
second doses. 
 
A relatively small proportion of participants were aged 65 years or over and the number of cases of 
Covid-19 in this age group was too small to assess protection based on the efficacy data alone. There 
were no cases of Covid-19 hospitalisation, severe COVID-19 disease, or Covid-19 death in participants 
with ≥65 years of age who received AZD1222. 
 
A summary of the main findings are presented in Table 1: 
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Table 1 Vaccine Efficacy for Incidence of First SARS-CoV-2 Virologically-confirmed COVID-19 Occurring ≥ 15 
Days Post Second Dose in the SDSD for Efficacy Analysis Set (Any Dosing Interval) Overall and by Subgroup 
(COV001 + COV002 + COV003 + COV0 
Analysis set 
Subgroup 








n / N (%) 
Control 
n / N (%) 
SDSD for efficacy analysis set, any dose interval 
Overall a 74 / 7201 (1.03) 197 / 7179 (2.74) 63.09 (51.81, 71.73) <0.001 
Age subgroup b 





189/6499 (2.9) 63.47 (51.95;72.23) <0.001 
Presence of comorbidity at baseline b, c 
Yes 28 / 2516 (1.11) 75 / 2540 (2.95) 61.87 (41.15, 75.29) <0.001 
No 46 / 4309 (1.07) 115 / 4227 (2.72) 61.62 (45.98, 72.73) <0.001 
Gender b 
Male 24 / 3285 (0.73) 82 / 3237 (2.53) 71.34 (54.85, 81.81) <0.001 
Female 50 / 3916 (1.28) 115 / 3942 (2.92) 56.97 (40.04, 69.12) <0.001 
Country b 
United Kingdom 23 / 3048 (0.75) 82 / 3136 (2.61) 71.70 (55.07, 82.17) <0.001 
Brazil 49 / 3414 (1.44) 112 / 3339 (3.35) 57.61 (40.73, 69.68) <0.001 
South Africa 2 / 739 (0.27) 3 / 704 (0.43) 37.13 (-276.69, 89.51) 0.611 
Time interval between Dose 1 and Dose 2 b 
≥ 4 to 8 weeks  54 / 4796 (1.13) 117 / 4662 (2.51) 56.42 (39.86, 68.43) <0.001 
9 to 12 weeks 11 / 1053 (1.04) 39 / 1101 (3.54) 70.48 (42.41, 84.87) <0.001 
> 12 weeks 8 / 1146 (0.70) 38 / 1213 (3.13) 77.62 (51.98, 89.57) <0.001 
 
Safety 
Note: The safety analysis reported in this document reflects data from DCO1 (data cut at 4 November 
2020) 
The overall safety of the AZD1222 vaccine is based on an interim analysis of pooled data from four 
clinical trials:   
2 trials conducted in the United Kingdom (phase I/II and phase II/ III), 1 in Brazil (phase III), and 1 in 
South Africa (phase I/II). At the time of analysis, safety data was available from 23,745 participants 
DRAFT prepared by the SAGE Working Group on COVID-19 vaccines  
10 February 2021  
 
11 
Background document for the Extraordinary meeting of the Strategic Advisory Group of Experts on 
Immunization (SAGE) – 08 February 2021 
 
≥18 years old, who had been randomized and received either the vaccine or control. Out of these, 
12,021 subjects received at least one dose of the vaccine, and 8,266 received two doses.  
 
At the time of analysis the median follow up time post-dose 1 was 105 days in the AZD1222 group and 
104 days in the control group.   . 
 
Demographic characteristics were generally similar among participants who received COVID-19 
Vaccine AstraZeneca and those who received control. Overall, among the participants who received 
COVID-19 Vaccine AstraZeneca, 90.3% were aged 18 to 64 years and 9.7% were 65 years of age or 
older. The majority of recipients were White (75.5%), 10.1% were Black and 3.5% were Asian; 55.8% 
were female and 44.2% male. 
Adverse reactions  
The majority of the adverse reactions were mild to moderate in severity and usually resolved within a 
few days of vaccination. When compared with the first dose, adverse reactions reported after the 
second dose were milder and less frequent. Reactogenicity was generally milder and less frequent in 
older adults (≥65 years old) compared to younger adults (18-64 years). Analyses of safety data by age, 
comorbidity, baseline seropositivity and country did not raise any specific concerns. 
 
The most frequently reported adverse reactions were injection site tenderness (63.7%), injection site 
pain (54.2%), headache (52.6%), fatigue (53.1%), myalgia (44.0%), malaise (44.2%), pyrexia (includes 
feverishness (33.6%) and fever >38°C (7.9%)), chills (31.9%), arthralgia (26.4%) and nausea (21.9%).   
The incidence of subjects with at least one local or systemic solicited event after any vaccination was 
highest on day 1 following vaccination, decreasing to 4% and 13 %, respectively, by day 7. The most 
common systemic solicited AEs at day 7 were fatigue, headache and malaise.  
 
• Very common (≥ 10%, may affect more than 1 in 10 people): headache, nausea, myalgia, 
arthralgia, injection site tenderness, injection site pain, injection site warmth, injection site 
pruritus, fatigue, malaise, pyrexia (including feverishness – very common, and fever ≥ 38° - 
common), chills  
 
• Common (≥ 1% to < 10%, may affect up to 1 in 10 people): injection site swelling, injection site 
erythema  
 
Safety data is limited in older subjects, particularly those ≥ 65 years. The frequency and severity of the 
solicited adverse events was lower in subjects ≥ 65 years, and the incidence of SAE and AESI was similar 
between <65 and ≥ 65 years.  There was no clinically relevant difference seen in the larger population 
of subjects that had at least one comorbidity.  
Adverse Events of Special Interest (AESI) 
Neuroinflammatory events 
A very small number of neuroinflammatory events have been reported following vaccination 
A causal relationship has not been established.  
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Neurological cases of interest  
A new diagnosis of multiple sclerosis was seen in the vaccine arm. Symptom onset was 10 days after 
the first dose. An MRI of the brain and spinal cord demonstrated multiple lesions. All but one of these 
lesions were not gadolinium-enhancing suggesting that most lesions pre-dated the vaccine dose.  A 
likely case of ‘short segment inflammatory myelitis’ was seen in the vaccine arm, although the 
diagnosis is not certain. The symptom onset was 14 days after the second vaccine dose.  Based on the 
available data, a causal association between the vaccine and the two cases cannot be concluded with 
certainty. 
A case of ‘transverse myelitis’ was seen in the control group. The symptom onset was 54 days after 
the first control dose. Two cases of trigeminal neuralgia were seen in the control group.  
Facial palsies  
Six cases of facial paralysis were seen, three each in the vaccine and control group. The three cases in 
the vaccine group were all one-sided ‘facial nerve palsies’, two had features suggesting they were not 
related to vaccination (one case is considered related to chronic suppurative otitis media / mastoiditis 
and the other occurred 80 days after vaccination).  
 
‘Neuroinflammatory conditions’ is included in the RMP as an important potential risk and will be 
closely monitored by routine and additional pharmacovigilance activities.  
 
Serious Adverse Events (SAEs) 
Five SAEs were considered related by the investigator, of which two were in the vaccine group (pyrexia, 
and transverse myelitis) and three were in the control group (autoimmune haemolytic anaemia, C-
reactive protein increased and myelitis) 
Special Considerations 
Pregnancy 
Pregnancy was reported for 21 subjects; 12 in the vaccine and 9 in the control group. 5 cases ended 
in spontaneous abortion – 2 in the vaccine and 3 in the control group.  
 
Animal studies of potential toxicity to reproduction and development have not been completed. 
Preliminary preclinical studies do not indicate harmful effects on fertility, pregnancy, embryo-foetal 
development, parturition or postnatal development.  
 
A pregnancy sub-study, and pregnancy registry are planned. 
  
Administration of vaccine in pregnancy should only be considered when the potential benefits 
outweigh any potential risks for the mother and foetus. 
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Breastfeeding 
It is unknown whether the vaccine is excreted in human milk. 
 
Paediatric population  
No data is available in subjects less than 18 years of age.  
Immunosuppression  
No data is currently available in immunocompromised subjects including those receiving 
immunosuppressant therapy. The efficacy of the vaccine may be lower in immunosuppressed 
individuals. Safety data is awaited in a subgroup of HIV positive subjects. 
  
Safety related to vaccine interactions  
No data are available on use of the vaccine with concomitant vaccines, including influenza vaccines. 
Licensed seasonal influenza and pneumococcal vaccinations were permitted at least 7 days before or 
after the study vaccine. 
 
Considerations for vaccinating older adults (age ≥ 65 years) 
 
Vaccine efficacy in older adults aged ≥65 years  is uncertain, because only 9.8% of the trial participants 
were 65 or older. This sample size was too small to estimate vaccine efficacy in this age group with 
precision given that the attack rate in this age group was lower (e.g., due to shielding behaviours). 
Only 8 cases in the control arm and 4 cases in the vaccine arm were observed >= 15 days after the 
second dose of vaccine based on the 7 December 2020 data cut, yielding a vaccine efficacy of 51.91% 
(95% CI: -59.98 to 85.54%). Efficacy was observed starting from day 22 after the first dose. While a 
longer interval between doses increased efficacy and immunogenicity, such data are not available for 
older persons as most older persons received a shorter inter-dose interval of 4-6 weeks. No cases of 
COVID-19 requiring hospitalisation were recorded among those receiving 2 doses of the vaccine 
compared with 2 in the control group in this age group. Safety data from 1169 vaccine recipients in 
this age group indicate the vaccine is well tolerated with no concerning safety signals, although 
detection of rare outcomes will require continued safety monitoring during the ongoing phase 3 trials 
and programmatic use of the vaccine. Immunogenicity data from phase 1/2 studies indicates high 
seroconversion rates by S-binding antibodies after the first SD (97.8%) and the second SD (100%) in 
older adults, and T cell responses were comparable in older and younger age groups[3-7].  
The majority of COVID-19 deaths globally have been among older adults aged 65+, as a result of an 
infection fatality rate that rises exponentially with age[9, 10]. Older adults are therefore identified as 
a  priority population in the WHO SAGE Roadmap for Prioritising Uses of COVID-19 Vaccines in the 
Context of Limited Supply[11]. This prioritisation is supported by vaccine impact modelling work, 
including scenarios with substantially reduced vaccine efficacy in older adults[12].   
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 Emerging Virus Variants of Concern 
SARS-CoV-2 viruses undergo evolution. Some new virus variants may be associated with higher 
transmissibility, disease severity, risk of reinfection, or a change in antigenic composition resulting in 
lower vaccine effectiveness.  
AZD1222 was designed around the SARS-CoV-2 prototype virus identified in November 2019. The 
SARS-CoV-2 spike gene has accumulated mutations, including within the receptor binding domain 
(RBD) and N-terminal domains (NTD), which are major targets of the immune response. The RBD 
mutations include the N501Y mutation which is associated with increased affinity for the angiotensin 
converting enzyme-2 (ACE2); while the E484K and K417N RBD mutations and mutations in the NTD 
have been associated with neutralising antibody escape (13).  
The N501Y.V1 (B.1.1.7) lineage, first identified in the United Kingdom (UK), included the N501Y 
mutation which has been associated with 53% increased transmissibly compared to earlier variants 
(14). The B.1.1.7 variant has further evolved to include the E484K mutation in the UK.  
 
The N501Y.V2 (B.1.351) lineage first identified in South Africa contains three RBD and NTD mutations 
(L18F, D80A, D215G, R246I) and a three amino acid deletion from positions 242 to 244). Comparison 
of the sensitivity of B.1.351 relative to original lineage virus to neutralizing antibodies from 
convalescent donors infected with the original lineage virus using a spike-pseudotyped neutralization 
(PSVA) assay demonstrated 48% of sera were unable to neutralize B.1.351, with the rest showing 3 to 
86-fold reduction in neutralization (15). This was corroborated using a live virus neutralisation assay 
(LVNA), with reduction in antibody activity ranging from 6-fold to knockout for the B.1.351 variant(16).  
A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 infection in the 
UK from November 2020 with a transmission advantage over the previous variants of the virus.  
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows 
that AZD1222 vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently 
circulating in the UK to previously circulating variants 
(https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160). The protection against 
symptomatic infection was similar despite lower neutralising antibody titres in vaccinated individuals 
against the B.1.1.7 variant than the 'Victoria’ strain of virus, e.g. the original strain identified in Wuhan. 
 
In the South African multi-site, randomised, double-blinded, placebo-controlled Phase I/IIa trial on 
safety and efficacy of AZD1222  vaccine in young healthy adults age 18 to <65 years, dose two serum 
samples (n=26) were tested by pseudotyped (PSVA) and live virus (LVNA) neutralisation assay for 
neutralization activity against the B.1.351 and D614G variant. At the time of writing, this analysis had 
not been peer-reviewed, and was only available as preprint. B.1.351 variant showed high resistance 
to vaccinee sera on the PSVA and LVNA. In the primary objective analysis, 23 (3.2%) of 717 placebo 
recipients and 19 (2.5%) of 750 vaccinees developed mild-moderate Covid-19; VE 21.9% (95% CI: -49.9; 
59.8). Thirty-nine (92.9%) of the 42 primary endpoint cases were due to the B.1.351 variant; against 
which VE was 10.4% (95% CI: -76.8; 54.8).  
 
Although this study indicates that AZD1222 vaccine does not protect against mild-moderate Covid-19 
caused by B.1.351 variant, extrapolating from immunological insights, it may still protect against 
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severe Covid-19. Other vaccine induced immune mediators, such as Th1 dominated cell mediated 
immune responses including T helper cytotoxic CD8+ cells, may play a more central role in reducing 
the risk of severe Covid-19 rather than neutralizing antibodies alone. 
 
Indirect evidence is compatible with protection against severe COVID-19, however, this remains to be 
demonstrated in ongoing clinical trials and post-implementation evaluations. These preliminary 
findings highlight the urgent need for a coordinated approach for surveillance and evaluation of 
variants and their potential impact on vaccine effectiveness. WHO will continue to monitor the 
situation; as new data become available, recommendations will be updated accordingly. 
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The annexes contain the grading of recommendations, assessment, development and evaluations – 
GRADE tables (Annex 1 to 6) and the SAGE evidence-to-recommendation framework tables – ETR 
tables (Annex 7-9). The ETR tables are based on the DECIDE Work Package 5: Strategies for 
communicating evidence to inform decisions about health system and public health interventions. 
Evidence to a recommendation (for use by a guideline panel) (www.decide-collaboration.eu/, 
accessed 11 January 2021). 
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Annex 1 GRADE table: Efficacy of AZD1222 COVID-19 vaccine in adults  
 
Population : Adults (18–64 years) 
Intervention: Two doses of AZD1222 vaccine 
Comparison: Placebo/ active control 
Outcome    : COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of AZD1222 vaccine compared with placebo/active control in 
preventing PCR-confirmed COVID-19 in adults (18–64 years)? 
    Rating Adjustment to rating 
   
















study designa Not serious
b 0 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  












 Statement on quality of evidence 
Evidence supports a high level of confidence 
that the true effect lies close to that 
of the estimate of the effect on the health 
outcome (level 4, or ⊕⊕⊕⊕). 
Conclusion 
We are very confident that 2 doses of AZD1222 
vaccine are efficacious in preventing PCR-









a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), 
please see www.covid-nma.com/vaccines. 
b Data on long-term protection emerging from the ongoing phase 3 clinical trial remain limited, as trial data 
have so far been reported only for a follow-up of approximately 2 months. This was considered as not 
constituting a limitation that would lead to downgrading of the evidence. SAGE will continue to review any 
emerging data and adjust its quality assessment as required. 
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Annex 2 GRADE table: Safety of AZD1222 COVID-19 vaccine in adults 
 
Population :  Adults (18–64 years) 
Intervention: One or two doses of AZD1222 vaccine 
Comparison: Placebo/ active control vaccination 
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following AZD1222 vaccination compared with 
placebo/ active control in adults (18–64 years)? 
    Rating Adjustment to rating 
   


















Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  












 Statement on quality of evidence 
Evidence supports a moderate level of 
confidence that the true effect lies close 
to that of the estimate of the effect on the health 
outcome (level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that the risk of serious 
adverse events following one or two doses of 










a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), 
please see www.covid-nma.com/vaccines. 
b Downgraded for the following limitations: The trial was not adequately powered to detect rare adverse 
events (i.e. less than about 1/2000). These may emerge only when large populations have been vaccinated. 
Limited follow-up time of clinical trial, which may not allow detection of adverse events occurring several 
months after vaccination.  
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Annex 3 GRADE table: Efficacy of AZD1222 COVID-19 vaccine in older adults 
 
Population :  Older adults (≥65 years) 
Intervention: Two doses of AZD1222 vaccine 
Comparison: Placebo/ active control  
Outcome     : COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of AZD1222 vaccine compared with placebo/ active control 
in preventing PCR-confirmed COVID-19 in older adults (≥65 years)? 
    Rating Adjustment to rating 
   
















study designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Seriousb -2 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  













Statement on quality of evidence 
Evidence supports a limited level of confidence 
that the true effect lies close to 
that of the estimate of the effect on the health 
outcome (level 2, or ⊕⊕). 
Conclusion 
We have low confidence in the evidence indicating 
that 2 doses of AZD1222 vaccine are efficacious in 
preventing PCR-confirmed COVID-19 in older 






a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), 
please see www.covid-nma.com/vaccines. 
b Of the trial participants, approximately 10% (n= 1380) were aged over 65 years. While supportive evidence 
(immunogenicity data in this age group) suggest that the vaccine elicits an immune response comparable to 
older adults, the trial did not show a statistically significant vaccine efficacy in this age-group. The very serious 
imprecision due to large confidence intervals and the limited sample size  were considered as factors 
constituting a limitation that leads to downgrading of the evidence. Data on long-term protection emerging 
from the ongoing phase 3 clinical trial remain limited, as trial data have so far been reported only for a follow-
up of approximately 2 months. This was considered as not constituting a limitation that would lead to 
downgrading of the evidence. SAGE will continue to review any emerging data and adjust its quality 
assessment as required. 
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Annex 4 GRADE table: Safety of AZD1222 COVID-19 vaccine in older adults 
 
 
Population :  Older adults (≥65 years) 
Intervention: One or two doses of AZD1222 vaccine 
Comparison: Placebo/ active control  
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following AZD1222 vaccination compared with 
placebo/ active control in older adults (≥65 years)? 
    Rating Adjustment to rating 
   


















Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Seriousc -1 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  













Statement on quality of evidence 
Evidence supports a limited level of confidence 
that the true effect lies close to 
that of the estimate of the effect on the health 
outcome (level 2, or ⊕⊕). 
Conclusion 
We have low confidence in the quality of evidence 
that the risk of serious adverse events following one 
or two doses of AZD1222 vaccine in older adults 









a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), 
please see www.covid-nma.com/vaccines. 
b Downgraded for the following limitations: The trial was not adequately powered to detect rare adverse 
events (i.e, about 1/250). These may emerge only when large populations have been vaccinated. Limited 
follow-up time of clinical trial, which may not allow detection of adverse events occurring several months after 
vaccination.. 
c Of the trial participants, approximately 10% (n= 1380) were aged over 65 years. This was considered as 
constituting a limitation that leads to downgrading of the evidence.  
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Annex 5 GRADE table: Efficacy of AZD1222 COVID-19 vaccine in individuals with underlying 
conditions 
Population :  Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: Two doses of AZD1222 vaccine 
Comparison: Placebo/ active control 
Outcome     : COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of AZD1222 vaccine compared with placebo/ active control 
in preventing PCR-confirmed COVID-19 in individuals with comorbidities or health states that 
increase risk for severe COVID-19? 
    Rating Adjustment to rating 
   
















study designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Seriousb  -1 
Imprecision Not seriousc 0 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  











s Statement on quality of evidence 
Evidence supports a moderate level of 
confidence that the true effect lies close 
to that of the estimate of the effect on the health 
outcome (level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that 2 doses of 
AZD1222 vaccine are efficacious in preventing 
PCR-confirmed COVID-19 in individuals with 
comorbidities or health states that increase risk for 
severe COVID-19 as included in the clinical trial. No 
data were obtained on vaccination of pregnant or 







a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised. Although persons with 
HIV were included in the trial, they were not included in the analyses. This was considered as constituting a limitation that 
leads to downgrading of the evidence.  
c Underlying comorbidities included BMI ≥ 30 kg/m2, cardiovascular disorder, respiratory disease or diabetes. 
Approximately 36% of the trial population had at least one comorbidity. This was considered as not constituting a 
limitation that would lead to downgrading of the evidence. Data on long-term protection emerging from the ongoing 
phase 3 clinical trial remain limited, as trial data have so far been reported only for a follow-up of approximately 2 months. 
This was considered as not constituting a limitation that would lead to downgrading of the evidence. SAGE will 
continue to review any emerging data and adjust its quality assessment as required. 
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Annex 6 GRADE table: Safety of AZD1222 COVID-19 vaccine in individuals with underlying conditions 
 
Population :  Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: One or two doses of AZD1222 vaccine 
Comparison: Placebo/ active control 
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following AZD1222 vaccination compared with 
placebo/ active control in individuals with comorbidities or health states that increase risk for 
severe COVID-19? 
    Rating Adjustment to rating 
   


















Inconsistency Not serious 0 
Indirectness Seriousc -1 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable   0  
Antagonistic bias 
and confounding Not applicable   0  













Statement on quality of evidence 
Evidence supports a limited level of confidence 
that the true effect lies close to 
that of the estimate of the effect on the health 
outcome (level 2, or ⊕⊕). 
Conclusion 
We have low confidence in the quality of evidence 
that the risk of serious adverse events in individuals 
with comorbidities or health states that increase risk 
for severe COVID-19 following one or two doses of 






a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for the following limitations: The trial was not adequately powered to detect rare adverse events (i.e. less 
than about 1/800). These may emerge only when large populations have been vaccinated. Limited follow-up time of 
clinical trial, which may not allow detection of adverse events occurring several months after vaccination. 
c Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised. Although persons with 
HIV were included in the trial, they were not included in the analyses. This was considered as constituting a limitation that 
leads to downgrading of the evidence.  
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Annex 7 SAGE evidence-to-recommendation framework: AZD1222 vaccine use in adults 
 
Question: Should AZD1222 vaccine be administered to adults to prevent COVID-19?  
Population:  Adults (18–64 years) 
Intervention:  Two doses of AZD1222 vaccine 
Comparison(s):  Active control/ placebo 
Outcome:  COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a public 
health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-being of individuals 
and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
Vaccines are considered to be a critical tool to combat the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim 
recommendations on the use of Pfizer-BioNTech and Moderna COVID-19 vaccine. (5;6) 
 
 






Is the problem 









The cumulative number of COVID-19 cases globally 
has surpassed 101 571 219 with more than 2 196 944 
deaths. Cases have been found in 190 different 
countries or territories throughout the world (status 
30 January 2021). There has been collateral damage to 
other public health programmes.   
 
The COVID-19 situation is evolving 
rapidly; the most recent epidemiological 














   





Using 07 December as data cut-off, primary efficacy 
analysis shows that AZD1222 vaccine is 63.1% (52.9%-
68.6%) efficacious across the study population. In 
The immunogenicity results from the 
phase 1/2 UK study, in 1077 healthy 
adults aged 18–55 years (2) and a phase 













☐ ☐ ☒ ☐ 
those 18-64 years of age, vaccine efficacy was 63.5 % 
(52.0-72.2). 
 
Vaccine efficacy in all participants varies by interval 
between first and second dose: 
<4 weeks interval:  66.56%  (-221.8, 96.5) 
4-8 weeks interval: 56.42% (39.9%-68.4%) 
9-12 weeks interval: 70.48% (42.4%-84.9%) 
>12 weeks interval: 77.62% (52%-89.6%) 
 
Vaccine efficacy against COVID-19 occurring ≥ 22 Days 
after the first dose (and before the second dose or up 
to 12 weeks post first dose) was 71.42% (51.11, 84.08) 




2 cohort in older adults (≥56 years)(3) 
show the induction of binding and 
neutralising antibodies, with higher 
antibody titres after a second dose of 
vaccine.(2;3;7) 
 
The vaccine further induced CD4+ and 
CD8+ T cells in adults aged 18–55 years, 
up to 8 weeks after vaccination with a 
single dose of AZD1222 nCoV-19 
vaccine.(8) 






effects small?  
No Un-
certain Yes Varies  
Data from over 12 021 participants demonstrate that 
AZD1222 vaccine was well tolerated across all 
populations.   
 
Overall, 86% of subjects in the vaccine group (Days 0-
7 after any vaccination) experienced at least one 
solicited AE compared to 72% in the control group. 
The majority of solicited AEs were mild or moderate. 
Ten percent of subjects in the vaccine group 
experienced at least one grade ≥3 local solicited 
adverse event (AE) and 8% at least one grade ≥3 
systemic solicited event compared with 6% and 3% in 
the control group, respectively. Solicited AEs were 
milder and reported less frequently after the second 
dose compared with the first. 
 
The most frequently reported systemic solicited AEs in 
the vaccine dose 1 standard-dose group after any 
vaccination were fatigue (53%) and headache (53%).  
 
Fewer than 1% of subjects reported a serious adverse 
event (SAE) and the reporting rate was balanced 
The results from the phase 1/2  
immunogenicity and safety trial suggest   
an acceptable safety profile in healthy 
adults aged 18–55 years (2) and a phase 
2 study in older adults (≥56 years)(3)  
☐ ☐ ☒ ☐ 
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between the two study groups (0.7% vaccine group, 
0.8% control).  
 
There were no clinically meaningful imbalances in SAE 
incidence for any subgroup (country, age, serostatus 
or comorbidity). 
 
There are no long-term safety data available yet and 


















Efficacy data suggest benefit, and short-term safety 
data suggest minimal harms. Further ongoing studies 
will need to be undertaken as part of post-marketing 
surveillance. 
 
☒ ☐ ☐ ☐ ☐ 

























☐ ☐ ☐ ☐ ☒ 
 
 
































































Available scientific evidence on the relative 
importance of the intervention, as well as the relative 
weights that the target population attributes to the 
desirable (i.e. protection conferred by the vaccine) 
and the undesirable outcomes (i.e. the currently 
reported safety signals), vary.  
 
Different population groups may have different 
opinions regarding the weights assigned to desirable 
and undesirable outcomes.  
 
 
☐ ☒ ☐ ☐ ☐ 






























Available scientific evidence suggests that target 
population assigns more weight to the desirable 
effects than to the undesirable effects related to 
COVID-19 vaccination. 
 





















Yes Varies  
AZD1222 can be distributed and stored using existing 
cold chain infrastructure (at 2°-8° C),(9) and does not 
require ultra-cold chain capacity. In addition, as 
AZD1222 can be manufactured with widely available 
manufacturing capacity around the world(10), its price 
is expected to be lower than for other COVID-19 
vaccines using new and less widely available 
manufacturing platforms.  Prices are also expected to 
be lower for AZD1222 compared to many other 
COVID-19 vaccines due to supplier commitments to 
forego profits.(11)  Nevertheless, considerable 
resources will be needed to ensure the 
implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-19 
vaccination is likely to be prioritized for populations 
(e.g. health care workers, older adults) without pre-
existing robust immunization programmes in many 
settings, and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional surge 
resources to accelerate implementation with 
adequate infection prevention and control procedures 
in the context of COVID-19. Resources required 
include, but are not restricted to, human resources, 
vaccine costs, logistics, planning and coordination, 
training, social mobilization and communications, and 
immunization safety surveillance.  
An estimated US$15.9 billion is needed 
for the vaccines pillar (COVAX) of the 
Access to COVID-19 Tools Accelerator 
(ACT-A) for 2020–21, when the initiative 
aims to deliver 2 billion doses. This does 
not include all delivery costs in all 
countries participating in COVAX, 
bilateral procurement deals, or research 
and development investments outside of 
COVAX (12). The World Bank has 
approved a financing window of up to 
US$12 billion to support low- and 
middle-income countries in purchasing 
and distributing vaccine (13). 
☒ ☐ ☐ ☐ 










certain Yes Varies 
Formal global cost-effectiveness analyses 
have not been conducted, but the emerging evidence 
indicates that the benefits, including the impact on 
recovery of the global economy, are likely to outweigh 
the cost of COVID-19 vaccination in general at global 
level.  
 
No formal cost-effectiveness analyses of AZD1222 
compared to other vaccines have been conducted. 
The AZD1222 vaccine is expected to be less costly than 
many other COVID-19 vaccines (see previous sub-
criterion).  Individual-level efficacy against COVID-19 
may be lower compared to some other COVID-19 
vaccines; more data are needed to assess efficacy 
against other endpoints (e.g., hospitalizations averted; 
see Background Paper). The ability to use AZD1222 in 
existing cold chain infrastructure in all country settings 
may enable higher population-level coverage.  
 
Cost-effectiveness analyses should be conducted at 
country level; cost-effectiveness of COVID-19 
vaccination may vary by country depending on COVID-
19 burden, comparator interventions assessed, 
analysis perspective, and local cost-effectiveness 
thresholds used. 
The global economy is estimated to be 
losing US$375 billion per month due to 
the coronavirus pandemic. G20 
countries have invested approximately 
US$10 trillion in domestic economic 
stimulus to mitigate the economic 
consequences of reduced business 
activity and unemployment due to the 
pandemic. Initial estimates suggest that 
COVID-19 vaccination will provide 
substantial economic value in terms of 
averted morbidity and mortality costs 
and averted GDP losses (12;14-20). 





What would be 








Equity and ethical considerations are critical. SAGE has 
produced a Values Framework (21), which offers 
guidance on the fair allocation of COVID-19 vaccines 
based on six core ethical principles that should guide 
distribution. If distributed fairly, COVID-19 vaccines 
may have considerable impact on reducing health 
inequities.   
 
Storage and distribution requirements of the AZD1222 
vaccine are the same as those of many other vaccines 
currently in use globally. Therefore existing vaccine 
cold chain capacity, available in almost all countries 
worldwide could be leveraged for vaccine distribution. 
Vaccine nationalism is seen as a threat to 
reducing health inequity, in particular as 
high-income countries have arranged 
bilateral contracts with manufacturers. 
This has led to the establishment of the  
Access to COVID-19 Tools (ACT) 
Accelerator and within this, the COVAX 
facility, which aims to ensure equitable 
access to vaccines for its participating 
member states (22). 
☐ ☐ ☒ ☐ 






























No scientific evidence is available. As vaccination is an 
eagerly awaited tool to combat COVID-19, it is 
assumed that key stakeholders, in particular ministries 
of health and immunization managers, are strongly in 
favour of it. 
 
190 economies are participating in 
COVAX suggests a very high acceptability 
of COVID-19 vaccination in general.   














COVID-19 vaccine acceptability in general varies 
between (sub-) population groups and may be 
correlated with the perceived risk posed by the 
disease. In a global survey (19 countries) of 
acceptance rates in the general population of any 
COVID-19 vaccine product, 71.5% of participants 
reported that they would be very or somewhat likely 
to take a COVID-19 vaccine. Acceptance rates ranged 
from almost 55% to 87% (23). 
 
Polls have been launched, (periodically) assessing 
(non-product specific) vaccine acceptance in selected 
countries. These polls confirm overall vaccine 

































This vaccine is assumed to be easily implementable  in 
settings, including low- and middle-income-countries, 
with existing vaccine logistics and delivery 
infrastructure. 
Administration of the vaccine to novel target groups 
currently not reached by national immunization 




☐ ☐ ☐ ☐ ☒ ☐ 















in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 







We suggest considering recommendation of the 
intervention 
 





and the comparison 
 




☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation 
(text) 
Vaccination with AZD1222 vaccine is recommended in persons aged 18 and above. In light of the observation that two-dose efficacy and 
immunogenicity increase with a longer interdose interval, WHO recommends an interval of 8 to 12 weeks between the doses. If the second dose is 
inadvertently administered less than 4 weeks after the first, the dose does not need to be repeated. If administration of the second dose is 
inadvertently delayed beyond 12 weeks, it should be given at the earliest possible opportunity. It is recommended that all vaccinated individuals 
receive two doses. 
 




















and research priorities 
WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− serious adverse events, anaphylaxis and other serious allergic reactions, Bell`s palsy, transverse myelitis, cases of multisystem 
inflammatory syndrome following vaccination, cases of COVID-19 following vaccination that result in hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in older persons; 
− vaccine effectiveness in relation to time interval between the first and second dose; 
− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with heterologous vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-cell and 
mucosal immunity assays. 
• Subpopulations: 
− prospective studies on the safety of AZD1222 vaccine in pregnant and lactating women; 
− randomized controlled trials on efficacy and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with autoimmune 
disease. 
• Vaccination logistics 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal vaccines, to 
adults and older persons; 
− safety, immunogenicity, and impact of a delayed second dose, as currently implemented by certain countries; 
− interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
− stability of vaccine under alternative cold-chain distribution and storage conditions.  
• Virus variants 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of vaccines; 
− Modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants 
− Booster studies with updated vaccine formulations.  
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Annex 8:SAGE evidence-to-recommendation framework: AZD1222 vaccine use in older adults 
 
 
Question: Should AZD1222 vaccine be administered to older adults to prevent COVID-19?  
Population:  Older adults (≥65 years) 
Intervention:  Two doses of AZD1222 vaccine 
Comparison(s):   Active control/ placebo 
Outcome:  COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a public 
health emergency of international concern in January 2020. The disease has since spread with an enormous impact on the health and well-being of individuals and 
populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
Vaccines are considered to be a critical tool to combat the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim 










Is the problem 










The cumulative number of COVID-19 cases globally 
has surpassed 101 571 219 with more than 2 196 944 
deaths. Cases have been found in 190 different 
countries or territories throughout the world (status 
30 January 2021). There has been collateral damage to 
other public health programmes. 
Older adults are particularly affected by COVID-19 and 
bear a significantly higher risk of severe COVID-19 
outcomes and death. 
The COVID-19 situation is evolving 
rapidly; the most recent epidemiological 






☐ ☐ ☒ ☐ 





































Around 10% of the study population in the primary 
analysis (data cut-off 07 December 2020; trial 
COV001,  COV002, COV003, COV005) were aged 65 
years or older. 
 
Primary efficacy analysis using SDSD at any interval 
shows that two doses of AZD1222 vaccine is 51.9% (-
60.9%-86.0%) efficacious in individuals aged 65 years 
and older against COVID-19 beginning 15 days after 
the second dose.   
 
A relatively small proportion of participants were aged 
65 years or over and the number of cases of Covid-19 
in this age group was too small to assess protection 
based on the efficacy data alone .  
 
There were no cases of Covid-19 hospitalisation, 
severe COVID-19 disease, or Covid-19 death in 








The immunogenicity results from the 
phase 1/2 UK study, in 1077 healthy 
adults aged 18–55 years (2) and a phase 
2 cohort in older adults (≥56 years)(3) 
show the induction of binding and 
neutralising antibodies, with higher 
antibody titres after a second dose of 
vaccine.(2;3;7) 
 
The vaccine further induced CD4+ and 
CD8+ T cells in adults aged 18–55 years, 
up to 8 weeks after vaccination with a 
single dose of AZD1222 nCoV-19 
vaccine.(8) 
☐ ☒ ☐ ☐ 






effects small?  
No Un-
certain Yes Varies  
Data from over 12 021 trial participants of all age 
demonstrate that AZD1222 vaccine was well tolerated 
across all populations.   
 
Overall, 86% of subjects in the vaccine group (Days 0-
7 after any vaccination) experienced at least one 
solicited AE compared to 72% in the control group. 
The majority of solicited AEs were mild or moderate. 
Ten percent of subjects in the vaccine group 
experienced at least one grade ≥3 local solicited 
adverse event (AE) and 8% at least one grade ≥3 
systemic solicited event compared with 6% and 3% in 
the control group, respectively. Solicited AEs were 
 
☐ ☐ ☒ ☐ 
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milder and reported less frequently after the second 
dose compared with the first. 
 
Reactogenicity was generally milder and less frequent 
in older adults (≥65 years old) compared to younger 
adults (18-64 years). 
 
The most frequently reported systemic solicited AEs in 
the vaccine dose 1 standard-dose group after any 
vaccination were fatigue (53%) and headache (53%).  
 
Fewer than 1% of subjects reported a serious adverse 
event (SAE) and the reporting rate was balanced 
between the two study groups (0.7% vaccine group, 
0.8% control).  
 
There were no clinically meaningful imbalances in SAE 
incidence for any subgroup (country, age, serostatus 
or comorbidity). 
 
There are no long-term safety data available yet and 


















Evidence on efficacy data suggest some, though not 
significant benefit of the intervention, and short-term 
safety data suggest limited harms. Further ongoing 
studies will need to be undertaken as part of post-
marketing surveillance. 
 
☒ ☐ ☐ ☐ ☐ 














☐ ☐ ☒ ☐ ☐ 
 
 
Safety of the intervention 




































































The majority of severe disease occurs in older 
individuals. Available scientific evidence suggests that 
the target population probably considers the desirable 
effects, i.e. the potential protection conferred by the 
vaccine, more important than the undesirable effects, 




Different population groups may have different 
opinions regarding the weights assigned to desirable 







































Available scientific evidence suggests that the target 
population probably assigns more weight to the 
desirable effects than the undesirable effects related 
to COVID-19 vaccination. 
Targeted information campaigns should assess this 
aspect.  
With more data on vaccine efficacy in older adults 
being generated, the uncertainty around the 
importance of the desirable effects of the intervention 






















Yes Varies  
AZD1222 can be distributed and stored using existing 
cold chain infrastructure (at 2°-8° C),(9) and does not 
require ultra-cold chain capacity. In addition, as 
AZD1222 can be manufactured with widely available 
manufacturing capacity around the world(10), its price 
is expected to be lower than for other COVID-19 
An estimated US$15.9 billion is needed 
for the vaccines pillar (COVAX) of the 
Access to COVID-19 Tools Accelerator 
(ACT-A) for 2020–21, when the initiative 
aims to deliver 2 billion doses. This does 
not include all delivery costs in all 
☐ ☐ ☒ ☐ 
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vaccines using new and less widely available 
manufacturing platforms.  Prices are also expected to 
be lower for AZD1222 compared to many other 
COVID-19 vaccines due to supplier commitments to 
forego profits.(11)  Nevertheless, considerable 
resources will be needed to ensure the 
implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-19 
vaccination is likely to be prioritized for populations 
(e.g. health care workers, older adults) without pre-
existing robust immunization programmes in many 
settings, and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional surge 
resources to accelerate implementation with 
adequate infection prevention and control procedures 
in the context of COVID-19. Resources required 
include, but are not restricted to, human resources, 
vaccine costs, logistics, planning and coordination, 
training, social mobilization and communications, and 
immunization safety surveillance.  
countries participating in COVAX, 
bilateral procurement deals, or research 
and development investments outside of 
COVAX (12). 
 
The World Bank has approved a 
financing window of up to US $12 billion 
to support low- and middle-income 








Formal global cost-effectiveness analyses 
have not been conducted, but the emerging evidence 
indicates that the benefits, including the impact on 
recovery of the global economy, are likely to outweigh 
the cost of COVID-19 vaccination in general at global 
level.  
 
No formal cost-effectiveness analyses of AZD1222 
compared to other vaccines have been conducted. 
The AZD1222 vaccine is expected to be less costly than 
many other COVID-19 vaccines (see previous sub-
criterion).  Individual-level efficacy against COVID-19 
may be lower compared to some other COVID-19 
vaccines; more data are needed to assess efficacy 
against other endpoints (e.g., hospitalizations averted; 
see Background Paper). The ability to use AZD1222 in 
existing cold chain infrastructure in all country settings 
may enable higher population-level coverage.  
 
The global economy is estimated to be 
losing US$375 billion per month due to 
the coronavirus pandemic.  G20 
countries have invested approximately 
US$10 trillion in domestic economic 
stimulus to mitigate the economic 
consequences of reduced business 
activity and unemployment due to the 
pandemic. Initial estimates suggest that 
COVID-19 vaccination will provide 
substantial economic value in terms of 
averted morbidity and mortality costs 
and averted GDP losses (12;14-19). 
☐ ☐ ☐ ☒ 
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Cost-effectiveness analyses should be conducted at 
country level; cost-effectiveness of COVID-19 
vaccination may vary by country depending on COVID-
19 burden, comparator interventions assessed, 






What would be 








Equity and ethical considerations are critical. SAGE has 
produced a Values Framework (21), which offers 
guidance on the fair allocation of COVID-19 vaccines 
based on six core ethical principles that should guide 
distribution. If distributed fairly, COVID-19 vaccines 
may have considerable impact on reducing health 
inequities.   
 
Storage and distribution requirements of AZD1222 
vaccine is shared by many other vaccines currently in 
use globally. Therefore existing vaccine cold chain 
capacity, available in almost all countries worldwide, 
could be leveraged for vaccine distribution. 
 
Vaccine nationalism is seen as a threat to 
reducing health inequity, in particular as 
high-income countries have arranged 
bilateral contracts with manufacturers. 
This has led to the establishment of the  
Access to COVID-19 Tools (ACT) 
Accelerator and, within this, the COVAX 
facility, which aims to ensure equitable 
access to vaccines for its participating 
member states (22). 

























No scientific evidence is available. As vaccination is an 
eagerly awaited tool to combat COVID-19, it is 
assumed that key stakeholders, in particular ministries 
of health and immunization managers are strongly in 
favour of COVID-19 vaccination. 
But they may need to convince other partners or 
stakeholders to support COVID-19 immunization. 
190 economies are participating in 
COVAX suggests a very high acceptability 
of COVID-19 vaccination in general, 
though not necessarily of this vaccine in 
particular.   














COVID-19vaccine acceptability in general varies 
between (sub-) population groups and may be 
correlated with the perceived risk posed by the 
disease. In a global survey (19 countries) of 
acceptance rates in the general population of any 
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☒ ☐ ☐ ☐ ☐ 
COVID-19 vaccine product, 71.5% of participants 
reported that they would be very or somewhat likely 
to take a COVID-19 vaccine. Acceptance rates ranged 
from almost 55% to 87% (23). 
 
Polls have been launched, (periodically) assessing 
(non-product specific) vaccine acceptance in selected 
countries. These polls confirm overall vaccine 
































This vaccine is assumed to be easily implementable  in 
settings, including low- and middle-income-countries, 
with existing vaccine logistics and delivery 
infrastructure. 
Administration of the vaccine to novel target groups 
currently not reached by national immunization 
programmes may pose a challenge in certain settings.  
 
 









in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 
☐ ☐ ☐ ☒ ☐ 












We suggest considering recommendation of the 
intervention 
 





and the comparison 
 




☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation 
(text) 
Because a relatively small number of participants aged 65 years or over were recruited into the clinical trials, there were few cases of COVID-19 in 
either the vaccine or the control group in this age category, and thus the confidence interval on the efficacy estimate is very wide. More precise 
efficacy estimates for this age group are expected soon, from both ongoing trials and vaccine effectiveness studies in countries that are using this 
vaccine. Immune responses induced by the vaccine in older persons are well documented and similar to those in other age groups. This suggests it 
is likely that the vaccine will be found to be efficacious in older persons. The trial data indicate that the vaccine is safe for this age group. The risk of 
severe disease and death due to COVID-19 increases steeply with age. Older adults are identified as a priority group in the WHO SAGE Prioritization 
Roadmap. This prioritization is supported by vaccine impact modelling work , even for vaccine efficacy that is substantially below that observed 
among younger adults administered AZD1222. Taking the totality of available evidence into account, WHO recommends the vaccine for use in 








WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− serious adverse events, anaphylaxis and other serious allergic reactions, Bell`s palsy, transverse myelitis, cases of 
multisystem inflammatory syndrome following vaccination, cases of COVID-19 following vaccination that result in 
hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in older persons; 
− vaccine effectiveness in relation to time interval between the first and second dose; 










− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with heterologous vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-
cell and mucosal immunity assays. 
• Subpopulations: 
− prospective studies on the safety of AZD1222 vaccine in pregnant and lactating women; 
− randomized controlled trials on efficacy and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with 
autoimmune disease. 
• Vaccination logistics 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
− safety, immunogenicity, and impact of a delayed second dose, as currently implemented by certain countries; 
− interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
− stability of vaccine under alternative cold-chain distribution and storage conditions.  
• Virus variants 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of 
vaccines; 
− Modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants 
− Booster studies with updated vaccine formulations.  
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16 Comorbidity within the phase III trial was defined as BMI ≥ 30 kg/m2, cardiovascular disorder, respiratory disease or diabetes. 
Question: Should AZD1222 vaccine be administered to individuals with comorbidities or health states that increase risk for severe 
COVID-1916 to prevent COVID-19?   
Population:   Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention:  Two doses of AZD1222 vaccine 
Comparison(s):   Active control/ placebo 
Outcome:  COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a public 
health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-being of individuals 
and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
 
Vaccines are considered to be a critical tool to combat the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim 
recommendations on the use of Pfizer-BioNTech and Moderna COVID-19 vaccine. (5;6) 
 
 







Is the problem 









The cumulative number of COVID-19 cases globally 
has surpassed 101 571 219 with more than 2 196 944 
deaths. Cases have been found in 190 different 
countries or territories throughout the world (status 
The COVID-19 situation is evolving 
rapidly; the most recent epidemiological 
situation can be found on the following 
website: 
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☐ ☐ ☒ ☐ 
30 January 2021). There has been collateral damage to 
other public health programmes. 
Individuals with certain comorbidities are particularly 
affected by COVID-19 and bear a higher risk of severe 
COVID-19 outcomes and death. Identified risk factors 
include comorbidities such as hypertension, chronic 
cardiac disease, non-asthmatic chronic pulmonary 
disease, chronic kidney disease, liver disease and 
obesity (particularly a body mass index (BMI) >40). 
People with multiple comorbidities are at a higher risk 
of COVID-19-related adverse outcomes (26). Although 
the relative risk may be high for some conditions, the 
absolute risk for younger adults with comorbidities is 






































Approximately 36% of participants in the primary 
efficacy population, as well as of the overall study 
population, had at least one comorbidity at baseline. 
The most common comorbid conditions were obesity 
(54.4%), hypertension (17.4%), and asthma (16.7%). 
 
Primary efficacy analysis (shows that AZD1222 vaccine 
is 61.3% efficacious (95%CI: 41.2-75.3%) against 
COVID-19 beginning 15 days  after the second dose in 










The immunogenicity results from the 
phase 1/2 UK study, in 1077 healthy 
adults aged 18–55 years (2) and a phase 
2 cohort in older adults (≥56 years)(3) 
show the induction of binding and 
neutralising antibodies, with higher 
antibody titres after a second dose of 
vaccine.(2;3;7) 
 
The vaccine further induced CD4+ and 
CD8+ T cells in adults aged 18–55 years, 
up to 8 weeks after vaccination with a 
single dose of AZD1222 nCoV-19 
vaccine.(8) 
☐ ☐ ☒ ☐ 
Harms of the 
intervention No 
Un-
certain Yes Varies  
Overall, 86% of all subjects in the vaccine group (Days 
0-7 after any vaccination), independent of 
comorbidity, experienced at least one solicited AE 
 










effects small?  
☐ ☐ ☒ ☐ 
compared to 72% in the control group. The majority of 
solicited AEs were mild or moderate. Ten percent of 
subjects in the vaccine group experienced at least one 
grade ≥3 local solicited adverse event (AE) and 8% at 
least one grade ≥3 systemic solicited event compared 
with 6% and 3% in the control group, respectively. 
Solicited AEs were milder and reported less frequently 
after the second dose compared with the first. 
 
The most frequently reported systemic solicited AEs in 
the vaccine dose 1 standard-dose group after any 
vaccination were fatigue (53%) and headache (53%).  
 
Fewer than 1% of subjects reported a serious adverse 
event (SAE) and the reporting rate was balanced 
between the two study groups (0.7% vaccine group, 
0.8% control).  
 
There were no clinically meaningful imbalances in SAE 
incidence for any subgroup (country, age, serostatus 
or comorbidity). 
 
No data are currently available in 
immunocompromised subjects or in subjects taking 
immunosuppressants. Safety data is awaited in a 















Efficacy data suggest benefit, and the short-term 
safety data suggest minimal harms. Further studies 
will need to be undertaken as part of post-marketing 
surveillance. 
 
☒ ☐ ☐ ☐ ☐ 














☐ ☐ ☐ ☒ ☐ 
 
 
Safety of the intervention 




































































There is possibly important uncertainty related to the 
target population weighing of desirable and 
undesirable effects ( i.e. the protection conferred by 
the vaccine weighed against the currently reported 
safety signals, related to COVID-19 vaccination. 
 
Different population groups may have different 
opinions regarding the relative weights attributed to 
desirable and undesirable outcomes 
 
 
























Available scientific evidence suggests that the target 
population probably attached more weight to the 
desirable effects than the undesirable effects related 
to COVID-19 vaccination. 
 






















Yes Varies  
AZD1222 can be distributed and stored using existing 
cold chain infrastructure (at 2°-8° C),(9) and does not 
require ultra-cold chain capacity. In addition, as 
AZD1222 can be manufactured with widely available 
manufacturing capacity around the world(10), its price 
is expected to be lower than for other COVID-19 
vaccines using new and less widely available 
manufacturing platforms.  Prices are also expected to 
be lower for AZD1222 compared to many other 
COVID-19 vaccines due to supplier commitments to 
forego profits.(11)  Nevertheless, considerable 
resources will be needed to ensure the 
implementation of a COVID-19 vaccination 
An estimated US$15.9 billion is needed 
for the vaccines pillar (COVAX) of the 
Access to COVID-19 Tools Accelerator 
(ACT-A) for 2020–21, when the initiative 
aims to deliver 2 billion vaccine doses.  
This does not include all delivery costs in 
all countries participating in COVAX, 
bilateral procurement deals, or research 
and development investments outside of 
COVAX (12). 
 
The World Bank has approved a 
financing window of up to US$12 billion 
☐ ☐ ☒ ☐ 




Background document for the Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 08 February 2021 
 
programme, especially given: (i) that COVID-19 
vaccination is likely to be prioritized for populations 
(e.g. health care workers, older adults) without pre-
existing robust immunization programmes in many 
settings, and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional surge 
resources to accelerate implementation with 
adequate infection prevention and control procedures 
in the context of COVID-19. Resources required 
include, but are not restricted to, human resources, 
vaccine costs, logistics, planning and coordination, 
training, social mobilization and communications, and 
immunization safety surveillance.  
to support low- and middle-income 








Formal global cost-effectiveness analyses 
have not been conducted, but the emerging evidence 
indicates that the benefits, including the impact on 
recovery of the global economy, are likely to outweigh 
the cost of COVID-19 vaccination in general at global 
level.  
 
No formal cost-effectiveness analyses of AZD1222 
compared to other vaccines have been conducted. 
The AZD1222 vaccine is expected to be less costly than 
many other COVID-19 vaccines (see previous sub-
criterion).  Individual-level efficacy against COVID-19 
may be lower compared to some other COVID-19 
vaccines; more data are needed to assess efficacy 
against other endpoints (e.g., hospitalizations averted; 
see Background Paper). The ability to use AZD1222 in 
existing cold chain infrastructure in all country settings 
may enable higher population-level coverage.  
 
Cost-effectiveness analyses should be conducted at 
country level; cost-effectiveness of COVID-19 
vaccination may vary by country depending on COVID-
19 burden, comparator interventions assessed, 
analysis perspective, and local cost-effectiveness 
thresholds used. 
The global economy is estimated to be 
losing US$375 billion per month due to 
the coronavirus pandemic.  G20 
countries have invested approximately 
US$10 trillion in domestic economic 
stimulus to mitigate the economic 
consequences of reduced business 
activity and unemployment due to the 
pandemic. Initial estimates suggest that 
COVID-19 vaccination will provide 
substantial economic value in terms of 
averted morbidity and mortality costs 
and averted GDP losses (12;14-19) 
 
 







Equity and ethical considerations are critical. SAGE has 
produced a Values Framework (21), which offers 
Vaccine nationalism is seen as a threat to 
reducing health inequity, in particular as 
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What would be 
the impact on 
health 
inequities? 
☐ ☐ ☒ ☐ 
guidance on the fair allocation of COVID-19 vaccines 
based on six core ethical principles that should guide 
distribution. If distributed fairly, COVID-19 vaccines 
may have considerable impact on reducing health 
inequities.   
 
Storage and distribution requirements of AZD1222 
vaccine is shared by many other vaccines currently in 
use globally. Therefore existing vaccine cold chain 
capacity, available in almost all countries worldwide 
could be leveraged for vaccine distribution. 
 
high-income countries have arranged 
bilateral contracts with manufacturers. 
This has led to the establishment of the  
Access to COVID-19 Tools (ACT) 
Accelerator and, within this, the COVAX 
facility, which aims to ensure equitable 
access to vaccines for its  participating  

























No scientific evidence is available. As vaccination is an 
eagerly awaited tool to combat COVID-19, it is 
assumed that key stakeholders, in particular ministries 
of health and immunization managers are strongly in 
favour of COVID-19 vaccination. 
But they may need to convince other partners or 
stakeholders to support COVID-19 immunization.   
 
The fact that 190 economies are 
participating in  COVAX suggests a very 
high acceptability of COVID-19 
vaccination in general, though not 
necessarily of this vaccine in particular.   














COVID-19 vaccine acceptability in general varies 
between (sub-) population groups and may be 
correlated with the perceived risk posed by the 
disease. In a global survey (19 countries) of 
acceptance rates in the general population of any 
COVID-19 vaccine product, 71.5% of participants 
reported that they would be very or somewhat likely 
to take a COVID-19 vaccine. Acceptance rates ranged 
from almost 55% to 87% (23). 
 
Polls have been launched, (periodically) assessing 
(non-product specific) vaccine acceptance in selected 
countries. These polls confirm overall vaccine 
acceptance, with variations across countries. (24;25) 
 
☒ ☐ ☐ ☐ ☐ 



































This vaccine is assumed to be easily implementable  in 
settings, including low- and middle-income-countries, 
with existing vaccine logistics and delivery 
infrastructure. 
Administration of the vaccine to novel target groups 
currently not reached by national immunization 
programmes may pose a challenge in certain settings.  
 
 









in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 







We suggest considering recommendation of the 
intervention 
 





and the comparison 
 




☒ Only with targeted monitoring and evaluation 
☒ Only in specific contexts or specific (sub)populations 








Persons with comorbidities  
Certain comorbidities have been identified as increasing the risk of severe COVID-19 disease and death. The Phase 3 clinical trial demonstrated that 
the vaccine has similar safety and efficacy profiles in persons with various underlying medical conditions, including those that place them at 
increased risk for severe COVID-19. The comorbidities studied in the Phase 3 clinical trials included obesity; cardiovascular disease; respiratory 




Immunocompromised persons are at higher risk of severe COVID-19. Available data are currently insufficient to assess vaccine efficacy or vaccine-
associated risks in severely immunocompromised persons including those receiving immunosuppressant therapy. It is possible that the immune 
response to the vaccine may be reduced, which may alter its effectiveness. In the interim, given that the vaccine is not a live virus vaccine, 
immunocompromised persons who are part of a group recommended for vaccination may be vaccinated. Information and, where possible, 




Pregnant women are at higher risk of severe COVID-19 compared to women of child-bearing age who are not pregnant, and COVID-19 has been 
associated with an increased risk of preterm birth. The available data on AZD1222 vaccination of pregnant women are insufficient to assess vaccine 
efficacy or vaccine-associated risks in pregnancy. However, it should be noted that the AZD1222 is non-replicating vaccine.  
Animal developmental and reproductive toxicity (DART) studies are ongoing. Based upon results from the preliminary findings, no harms are 
expected on the development of the fetus. Further studies are planned in pregnant women in the coming months including a pregnancy sub-study 
and a pregnancy registry. As data from these studies become available, recommendations on vaccination will be updated accordingly. In the interim, 
pregnant women should only receive AZD 1222 if the benefit of vaccination to the pregnant woman outweighs the potential vaccine risks, such as 
pregnant women who are health workers at high risk of exposure and pregnant women with comorbidities that already place them in a high-risk 
group for severe COVID-19. Information and, if possible, counselling on the lack of safety and efficacy data for pregnant women should be provided.  
WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy because of vaccination. 
 
Lactating women 
Breastfeeding offers substantial health benefits to lactating women and their breastfed children. Vaccine efficacy is expected to be similar in lactating 
women as in other adults. It is unknown whether AZD1222 is excreted in human milk. As the AZD1222 vaccine is non-replicating vaccine, it is 
unlikely to pose a risk to the breastfeeding child. On the basis of these considerations, a lactating woman who is part of a group recommended for 
vaccination, e.g. health workers, should be offered vaccination on an equivalent basis. WHO does not recommend discontinuing breastfeeding after 
vaccination.  
 
Persons living with HIV 
Persons living with HIV may be at higher risk of severe COVID-19. Persons living with HIV were not included in the primary analyses of the Phase 
3 trials and safety data is awaited in a subgroup of HIV positive subjects. Data on administration of the vaccine are currently insufficient to allow 




Background document for the Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 08 February 2021 
 
assessment of vaccine efficacy or safety for persons living with HIV. It is possible that the immune response to the vaccine may be reduced, which 
may alter its effectiveness. In the interim, given that the vaccine is a non-replicating vaccine, persons living with HIV who are part of a group 
recommended for vaccination may be vaccinated. Information and, where possible, counselling should be provided to inform individual benefit–
risk assessment. It is not necessary to test for HIV infection prior to vaccine administration.  
 
Persons with autoimmune conditions  
No data are currently available on the safety and efficacy of AZD1222 in persons with autoimmune conditions. Persons with autoimmune conditions 
who have no contraindications to vaccination may be vaccinated.   
Implementation 
considerations 
Before implementation, countries should consider whether they have adequate logistic and cold-chain capacity in place to ensure vaccine 
distribution and administration under the mentioned requirements. In the countries where various immunization stakeholders have a crucial role 




WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− serious adverse events, anaphylaxis and other serious allergic reactions, Bell`s palsy, transverse myelitis, cases of multisystem 
inflammatory syndrome following vaccination, cases of COVID-19 following vaccination that result in hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in older persons; 
− vaccine effectiveness in relation to time interval between the first and second dose; 
− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with heterologous vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-cell and 
mucosal immunity assays. 
• Subpopulations: 
− prospective studies on the safety of AZD1222 vaccine in pregnant and lactating women; 
− randomized controlled trials on efficacy and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with autoimmune 
disease. 
• Vaccination logistics 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal vaccines, to 
adults and older persons; 
− safety, immunogenicity, and impact of a delayed second dose, as currently implemented by certain countries; 
























− interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
− stability of vaccine under alternative cold-chain distribution and storage conditions.  
• Virus variants 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of vaccines; 
− Modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants 
− Booster studies with updated vaccine formulations.  
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